LONG MINI-FUTURE - GENMAB | Delayed Börse Stuttgart 11:52:57 25/06/2024 am IST | ||
| 10.72 EUR | -6.86% |
|
| Current month | -15.99% | ||
| 1 month | -23.43% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 25/24/25 | 10.72 | -6.86% |
| 24/24/24 | 11.51 | +8.89% |
| 20/24/20 | 10.57 | -5.12% |
| 19/24/19 | 11.14 | +1.09% |
| 18/24/18 | 11.02 | -1.87% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 11:52 am IST
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VA8X42 |
| ISIN | DE000VA8X421 |
| Date issued | 29/10/2018 |
| Strike | 965 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.81 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 32.89 € |
|---|---|
| Lowest since issue | 1.54 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,799
DKK
Average target price
2,464
DKK
Spread / Average Target
+36.96%
- Stock Market
- Certificates
- Certificat
